First published · Last updated
Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran
Journal article published by Elsevier presenting a cost-effectiveness comparison of carfilzomib versus bortezomib for relapsed/refractory multiple myeloma in Iran. The supplied source data include no methodological details, sample sizes, or results.
Categories: public-health, economy-and-trade
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 6/10
- Geographic reach
- 4/10
- Global importance
- 3/10
- Impact magnitude
- 3/10
- Positivity
- 6/10
- Urgency
- 2/10
Why it matters
It matters because it reports a cost-effectiveness comparison of cancer treatments specific to Iran.

